Notification of trade among primary insiders
Reference is made to the notice to the stock exchange on 3 November 2010 regarding commencement of subscription period for the “Subsequent repair offering”. On 17 November 2010 mandatory notification of trade among primary insiders of DiaGenic ASA took place. The transactions are described in detail below.
Maria Holmlund, board member in DiaGenic ASA, has received 11,756 subscription rights in the subsequent repair issue. Holmlund has subscribed for 11,756 shares in the subsequent repair offering at NOK 0.50 per share. Holmlund’s holding in the Company will increase from 11,000 shares to 22,756 shares post allotment of the shares in the offering.
Derek Tobin, senior scientist in DiaGenic ASA, has received 8,550 subscription rights in the subsequent repair issue. Tobin has subscribed for 10,000 shares in the subsequent repair offering at NOK 0.50 per share. Tobin’s holding in the Company will increase from 8,000 shares to minimum 16,550 shares and maximum 18,000 shares post allotment of the shares in the offering.
Torbjørn Lindahl, bioinformatics manager in DiaGenic ASA, has received 41,148 subscription rights in the subsequent repair issue. Lindahl has sold 41,148 subscription rights at NOK 0.11 per subscription right. This transaction does not alter Lindahl’s holding in the Company, which consist of 38,500 shares.
Contact:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com